Key facts
- Atalanta Therapeutics’s last known valuation is $45.0M (Jun 2018).
- It has raised $227.0M; the latest was Later Stage VC ($97.0M) in Jan 2025.
- Notable investors include F-Prime Capital, Mirae Asset Capital, EQT Life Sciences, Novartis Venture Fund, Pictet — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Atalanta Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Atalanta Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atalanta Therapeutics
Developer of targeted RNA-modulating therapeutics designed for the treatment of genetically defined diseases. The company utilizes proprietary structure-switching molecules to modulate gene expression, including oncology, neurology, and rare genetic disorders, enabling the biopharmaceutical industries to address previously undruggable targets across multiple disease areas.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2018
- Employees
- 55
- Website
- atalantatx.com/
- Ownership
- Privately Held (backing)
Atalanta Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atalanta Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atalanta Therapeutics in its N-PORT filings yet. We sweep new filings monthly.